Expression and clinical significance of annexin A2 and human epididymis protein 4 in endometrial carcinoma
It is well-known that the treatment and monitoring methods are limited for advanced stage of endometrial carcinoma. Biological molecules with expression changes during tumor progression become potential therapeutic targets for advanced stage endometrial carcinoma. Annexin A2 (ANXA2) has been reporte...
Gespeichert in:
| Veröffentlicht in: | Journal of experimental & clinical cancer research 2015-09, Vol.34 (1), p.96-96, Article 96 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 96 |
|---|---|
| container_issue | 1 |
| container_start_page | 96 |
| container_title | Journal of experimental & clinical cancer research |
| container_volume | 34 |
| creator | Deng, Lu Gao, Yiping Li, Xiao Cai, Mingbo Wang, Huimin Zhuang, Huiyu Tan, Mingzi Liu, Shuice Hao, Yingying Lin, Bei |
| description | It is well-known that the treatment and monitoring methods are limited for advanced stage of endometrial carcinoma. Biological molecules with expression changes during tumor progression become potential therapeutic targets for advanced stage endometrial carcinoma. Annexin A2 (ANXA2) has been reported to be overexpressed in recurrent endometrial carcinoma, and the expression of human epididymis protein 4 (HE4) is upregulated in endometrial carcinoma. What's more, ANXA2 and HE4 interacted in ovarian cancer and promoted the malignant biological behavior. We speculated that their interaction may exist in endometrial carcinoma as well. We evaluated the expression and the correlation relationship of ANXA2 and HE4 in endometrial carcinoma.
The expression of ANXA2 and HE4 protein in 84 endometrial carcinoma, 30 endometrial atypical hyperplasia, and 18 normal endometrial tissue samples were then measured using an immunohistochemical assay in paraffin embedded endometrial tissues. The structural relationship between ANXA2 and HE4 was explored by immunoprecipitation and double immunofluorescent staining.
ANXA2 and HE4 co-localized in both endometrial tissues and endometrial carcinoma cells. ANXA2 and HE4 were expressed in 95.2 % and 85.7 % of the the endometrial carcinoma, respectively, which were significantly higher than normal endometrium (55.6 % and 16.7 %, both p |
| doi_str_mv | 10.1186/s13046-015-0208-8 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4567805</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A541579659</galeid><sourcerecordid>A541579659</sourcerecordid><originalsourceid>FETCH-LOGICAL-c525t-90b56e4c6c8c3b19e615db75bebab0ebd79838f7a40c4625796e7d5d3d03fc953</originalsourceid><addsrcrecordid>eNptkl1rHCEUhqW0NGnaH9CbMlAovZlUndHRm8IS0g8I9Ka9FkfP7Lo4OtWZkPz7Ot003S1F0IPnOa-c44vQa4IvCRH8QyYNbnmNCasxxaIWT9A56RivpeT86VF8hl7kvMeYE0nkc3RGecOpbMQ52l_fTQlydjFUOtjKeBec0b7KbhvcUMJgoIpDSQa4c6Ha0N_cbhl1qGBy1tn70eVqSnGGkm-rskGwcYQ5uSJkdDIuxFG_RM8G7TO8ejgv0I9P19-vvtQ33z5_vdrc1IZRNtcS94xDa7gRpumJBE6Y7TvWQ697DL3tpGjE0OkWm5ZT1kkOnWW2sbgZjGTNBfp40J2WfgRrIMxJezUlN-p0r6J26jQT3E5t461qGe8EXgXePwik-HOBPKvSoAHvdYC4ZEU6QhklZbAFffsPuo9LCqW9QglMCKOi_UtttQflwhDLu2YVVRvWkrUFJgt1-R-qLAujMzHA4Mr9ScG7o4IdaD_vcvTLXD4zn4LkAJoUc04wPA6DYLU6SR2cpIqT1OokJUrNm-MpPlb8sU7zC2rnw3Q</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1780115284</pqid></control><display><type>article</type><title>Expression and clinical significance of annexin A2 and human epididymis protein 4 in endometrial carcinoma</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>SpringerNature Journals</source><source>PubMed Central Open Access</source><source>Springer Nature OA Free Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Deng, Lu ; Gao, Yiping ; Li, Xiao ; Cai, Mingbo ; Wang, Huimin ; Zhuang, Huiyu ; Tan, Mingzi ; Liu, Shuice ; Hao, Yingying ; Lin, Bei</creator><creatorcontrib>Deng, Lu ; Gao, Yiping ; Li, Xiao ; Cai, Mingbo ; Wang, Huimin ; Zhuang, Huiyu ; Tan, Mingzi ; Liu, Shuice ; Hao, Yingying ; Lin, Bei</creatorcontrib><description>It is well-known that the treatment and monitoring methods are limited for advanced stage of endometrial carcinoma. Biological molecules with expression changes during tumor progression become potential therapeutic targets for advanced stage endometrial carcinoma. Annexin A2 (ANXA2) has been reported to be overexpressed in recurrent endometrial carcinoma, and the expression of human epididymis protein 4 (HE4) is upregulated in endometrial carcinoma. What's more, ANXA2 and HE4 interacted in ovarian cancer and promoted the malignant biological behavior. We speculated that their interaction may exist in endometrial carcinoma as well. We evaluated the expression and the correlation relationship of ANXA2 and HE4 in endometrial carcinoma.
The expression of ANXA2 and HE4 protein in 84 endometrial carcinoma, 30 endometrial atypical hyperplasia, and 18 normal endometrial tissue samples were then measured using an immunohistochemical assay in paraffin embedded endometrial tissues. The structural relationship between ANXA2 and HE4 was explored by immunoprecipitation and double immunofluorescent staining.
ANXA2 and HE4 co-localized in both endometrial tissues and endometrial carcinoma cells. ANXA2 and HE4 were expressed in 95.2 % and 85.7 % of the the endometrial carcinoma, respectively, which were significantly higher than normal endometrium (55.6 % and 16.7 %, both p < 0.05). The expression of ANXA2 and HE4 was significantly correlated with FIGO stage, degree of differentiation, myometrial invasion, and lymph node metastasis. ANXA2 was an independent risk factor for the prognosis of endometrial carcinoma (p < 0.05, hazard ratio [HR] = 8.004). The expression of ANXA2 and HE4 was positively correlated (Spearman correlation coefficient = 0.228, p < 0.05). HE4 was an independent factor for ANXA2 in multivariate linear regression model (p < 0.05).
We revealed the co-localization of ANXA2 and HE4 in endometrial carcinoma. Expression levels of ANXA2 and HE4 were closely related to the malignant biological behavior of endometrial carcinoma, and ANXA2 was an independent risk factor for poor prognosis. The expression of ANXA2 and HE4 can affect each other.</description><identifier>ISSN: 1756-9966</identifier><identifier>ISSN: 0392-9078</identifier><identifier>EISSN: 1756-9966</identifier><identifier>DOI: 10.1186/s13046-015-0208-8</identifier><identifier>PMID: 26362938</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Annexin A2 - metabolism ; Annexins ; Biomarkers, Tumor - metabolism ; Cancer ; Carcinoma ; Carcinoma - metabolism ; Carcinoma - secondary ; Care and treatment ; Complications and side effects ; Development and progression ; Endometrial Neoplasms - metabolism ; Endometrial Neoplasms - pathology ; Endometrium - metabolism ; Endometrium - pathology ; Female ; Health aspects ; Humans ; Immunohistochemistry ; Lymphatic Metastasis ; Neoplasm Invasiveness ; Ovarian cancer ; Patient outcomes ; Prognosis ; Proteins - metabolism ; Risk factors ; ROC Curve</subject><ispartof>Journal of experimental & clinical cancer research, 2015-09, Vol.34 (1), p.96-96, Article 96</ispartof><rights>COPYRIGHT 2015 BioMed Central Ltd.</rights><rights>Copyright BioMed Central 2015</rights><rights>Deng et al. 2015</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c525t-90b56e4c6c8c3b19e615db75bebab0ebd79838f7a40c4625796e7d5d3d03fc953</citedby><cites>FETCH-LOGICAL-c525t-90b56e4c6c8c3b19e615db75bebab0ebd79838f7a40c4625796e7d5d3d03fc953</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4567805/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4567805/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26362938$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Deng, Lu</creatorcontrib><creatorcontrib>Gao, Yiping</creatorcontrib><creatorcontrib>Li, Xiao</creatorcontrib><creatorcontrib>Cai, Mingbo</creatorcontrib><creatorcontrib>Wang, Huimin</creatorcontrib><creatorcontrib>Zhuang, Huiyu</creatorcontrib><creatorcontrib>Tan, Mingzi</creatorcontrib><creatorcontrib>Liu, Shuice</creatorcontrib><creatorcontrib>Hao, Yingying</creatorcontrib><creatorcontrib>Lin, Bei</creatorcontrib><title>Expression and clinical significance of annexin A2 and human epididymis protein 4 in endometrial carcinoma</title><title>Journal of experimental & clinical cancer research</title><addtitle>J Exp Clin Cancer Res</addtitle><description>It is well-known that the treatment and monitoring methods are limited for advanced stage of endometrial carcinoma. Biological molecules with expression changes during tumor progression become potential therapeutic targets for advanced stage endometrial carcinoma. Annexin A2 (ANXA2) has been reported to be overexpressed in recurrent endometrial carcinoma, and the expression of human epididymis protein 4 (HE4) is upregulated in endometrial carcinoma. What's more, ANXA2 and HE4 interacted in ovarian cancer and promoted the malignant biological behavior. We speculated that their interaction may exist in endometrial carcinoma as well. We evaluated the expression and the correlation relationship of ANXA2 and HE4 in endometrial carcinoma.
The expression of ANXA2 and HE4 protein in 84 endometrial carcinoma, 30 endometrial atypical hyperplasia, and 18 normal endometrial tissue samples were then measured using an immunohistochemical assay in paraffin embedded endometrial tissues. The structural relationship between ANXA2 and HE4 was explored by immunoprecipitation and double immunofluorescent staining.
ANXA2 and HE4 co-localized in both endometrial tissues and endometrial carcinoma cells. ANXA2 and HE4 were expressed in 95.2 % and 85.7 % of the the endometrial carcinoma, respectively, which were significantly higher than normal endometrium (55.6 % and 16.7 %, both p < 0.05). The expression of ANXA2 and HE4 was significantly correlated with FIGO stage, degree of differentiation, myometrial invasion, and lymph node metastasis. ANXA2 was an independent risk factor for the prognosis of endometrial carcinoma (p < 0.05, hazard ratio [HR] = 8.004). The expression of ANXA2 and HE4 was positively correlated (Spearman correlation coefficient = 0.228, p < 0.05). HE4 was an independent factor for ANXA2 in multivariate linear regression model (p < 0.05).
We revealed the co-localization of ANXA2 and HE4 in endometrial carcinoma. Expression levels of ANXA2 and HE4 were closely related to the malignant biological behavior of endometrial carcinoma, and ANXA2 was an independent risk factor for poor prognosis. The expression of ANXA2 and HE4 can affect each other.</description><subject>Annexin A2 - metabolism</subject><subject>Annexins</subject><subject>Biomarkers, Tumor - metabolism</subject><subject>Cancer</subject><subject>Carcinoma</subject><subject>Carcinoma - metabolism</subject><subject>Carcinoma - secondary</subject><subject>Care and treatment</subject><subject>Complications and side effects</subject><subject>Development and progression</subject><subject>Endometrial Neoplasms - metabolism</subject><subject>Endometrial Neoplasms - pathology</subject><subject>Endometrium - metabolism</subject><subject>Endometrium - pathology</subject><subject>Female</subject><subject>Health aspects</subject><subject>Humans</subject><subject>Immunohistochemistry</subject><subject>Lymphatic Metastasis</subject><subject>Neoplasm Invasiveness</subject><subject>Ovarian cancer</subject><subject>Patient outcomes</subject><subject>Prognosis</subject><subject>Proteins - metabolism</subject><subject>Risk factors</subject><subject>ROC Curve</subject><issn>1756-9966</issn><issn>0392-9078</issn><issn>1756-9966</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNptkl1rHCEUhqW0NGnaH9CbMlAovZlUndHRm8IS0g8I9Ka9FkfP7Lo4OtWZkPz7Ot003S1F0IPnOa-c44vQa4IvCRH8QyYNbnmNCasxxaIWT9A56RivpeT86VF8hl7kvMeYE0nkc3RGecOpbMQ52l_fTQlydjFUOtjKeBec0b7KbhvcUMJgoIpDSQa4c6Ha0N_cbhl1qGBy1tn70eVqSnGGkm-rskGwcYQ5uSJkdDIuxFG_RM8G7TO8ejgv0I9P19-vvtQ33z5_vdrc1IZRNtcS94xDa7gRpumJBE6Y7TvWQ697DL3tpGjE0OkWm5ZT1kkOnWW2sbgZjGTNBfp40J2WfgRrIMxJezUlN-p0r6J26jQT3E5t461qGe8EXgXePwik-HOBPKvSoAHvdYC4ZEU6QhklZbAFffsPuo9LCqW9QglMCKOi_UtttQflwhDLu2YVVRvWkrUFJgt1-R-qLAujMzHA4Mr9ScG7o4IdaD_vcvTLXD4zn4LkAJoUc04wPA6DYLU6SR2cpIqT1OokJUrNm-MpPlb8sU7zC2rnw3Q</recordid><startdate>20150911</startdate><enddate>20150911</enddate><creator>Deng, Lu</creator><creator>Gao, Yiping</creator><creator>Li, Xiao</creator><creator>Cai, Mingbo</creator><creator>Wang, Huimin</creator><creator>Zhuang, Huiyu</creator><creator>Tan, Mingzi</creator><creator>Liu, Shuice</creator><creator>Hao, Yingying</creator><creator>Lin, Bei</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20150911</creationdate><title>Expression and clinical significance of annexin A2 and human epididymis protein 4 in endometrial carcinoma</title><author>Deng, Lu ; Gao, Yiping ; Li, Xiao ; Cai, Mingbo ; Wang, Huimin ; Zhuang, Huiyu ; Tan, Mingzi ; Liu, Shuice ; Hao, Yingying ; Lin, Bei</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c525t-90b56e4c6c8c3b19e615db75bebab0ebd79838f7a40c4625796e7d5d3d03fc953</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Annexin A2 - metabolism</topic><topic>Annexins</topic><topic>Biomarkers, Tumor - metabolism</topic><topic>Cancer</topic><topic>Carcinoma</topic><topic>Carcinoma - metabolism</topic><topic>Carcinoma - secondary</topic><topic>Care and treatment</topic><topic>Complications and side effects</topic><topic>Development and progression</topic><topic>Endometrial Neoplasms - metabolism</topic><topic>Endometrial Neoplasms - pathology</topic><topic>Endometrium - metabolism</topic><topic>Endometrium - pathology</topic><topic>Female</topic><topic>Health aspects</topic><topic>Humans</topic><topic>Immunohistochemistry</topic><topic>Lymphatic Metastasis</topic><topic>Neoplasm Invasiveness</topic><topic>Ovarian cancer</topic><topic>Patient outcomes</topic><topic>Prognosis</topic><topic>Proteins - metabolism</topic><topic>Risk factors</topic><topic>ROC Curve</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Deng, Lu</creatorcontrib><creatorcontrib>Gao, Yiping</creatorcontrib><creatorcontrib>Li, Xiao</creatorcontrib><creatorcontrib>Cai, Mingbo</creatorcontrib><creatorcontrib>Wang, Huimin</creatorcontrib><creatorcontrib>Zhuang, Huiyu</creatorcontrib><creatorcontrib>Tan, Mingzi</creatorcontrib><creatorcontrib>Liu, Shuice</creatorcontrib><creatorcontrib>Hao, Yingying</creatorcontrib><creatorcontrib>Lin, Bei</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of experimental & clinical cancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Deng, Lu</au><au>Gao, Yiping</au><au>Li, Xiao</au><au>Cai, Mingbo</au><au>Wang, Huimin</au><au>Zhuang, Huiyu</au><au>Tan, Mingzi</au><au>Liu, Shuice</au><au>Hao, Yingying</au><au>Lin, Bei</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Expression and clinical significance of annexin A2 and human epididymis protein 4 in endometrial carcinoma</atitle><jtitle>Journal of experimental & clinical cancer research</jtitle><addtitle>J Exp Clin Cancer Res</addtitle><date>2015-09-11</date><risdate>2015</risdate><volume>34</volume><issue>1</issue><spage>96</spage><epage>96</epage><pages>96-96</pages><artnum>96</artnum><issn>1756-9966</issn><issn>0392-9078</issn><eissn>1756-9966</eissn><abstract>It is well-known that the treatment and monitoring methods are limited for advanced stage of endometrial carcinoma. Biological molecules with expression changes during tumor progression become potential therapeutic targets for advanced stage endometrial carcinoma. Annexin A2 (ANXA2) has been reported to be overexpressed in recurrent endometrial carcinoma, and the expression of human epididymis protein 4 (HE4) is upregulated in endometrial carcinoma. What's more, ANXA2 and HE4 interacted in ovarian cancer and promoted the malignant biological behavior. We speculated that their interaction may exist in endometrial carcinoma as well. We evaluated the expression and the correlation relationship of ANXA2 and HE4 in endometrial carcinoma.
The expression of ANXA2 and HE4 protein in 84 endometrial carcinoma, 30 endometrial atypical hyperplasia, and 18 normal endometrial tissue samples were then measured using an immunohistochemical assay in paraffin embedded endometrial tissues. The structural relationship between ANXA2 and HE4 was explored by immunoprecipitation and double immunofluorescent staining.
ANXA2 and HE4 co-localized in both endometrial tissues and endometrial carcinoma cells. ANXA2 and HE4 were expressed in 95.2 % and 85.7 % of the the endometrial carcinoma, respectively, which were significantly higher than normal endometrium (55.6 % and 16.7 %, both p < 0.05). The expression of ANXA2 and HE4 was significantly correlated with FIGO stage, degree of differentiation, myometrial invasion, and lymph node metastasis. ANXA2 was an independent risk factor for the prognosis of endometrial carcinoma (p < 0.05, hazard ratio [HR] = 8.004). The expression of ANXA2 and HE4 was positively correlated (Spearman correlation coefficient = 0.228, p < 0.05). HE4 was an independent factor for ANXA2 in multivariate linear regression model (p < 0.05).
We revealed the co-localization of ANXA2 and HE4 in endometrial carcinoma. Expression levels of ANXA2 and HE4 were closely related to the malignant biological behavior of endometrial carcinoma, and ANXA2 was an independent risk factor for poor prognosis. The expression of ANXA2 and HE4 can affect each other.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>26362938</pmid><doi>10.1186/s13046-015-0208-8</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1756-9966 |
| ispartof | Journal of experimental & clinical cancer research, 2015-09, Vol.34 (1), p.96-96, Article 96 |
| issn | 1756-9966 0392-9078 1756-9966 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4567805 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; SpringerNature Journals; PubMed Central Open Access; Springer Nature OA Free Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Annexin A2 - metabolism Annexins Biomarkers, Tumor - metabolism Cancer Carcinoma Carcinoma - metabolism Carcinoma - secondary Care and treatment Complications and side effects Development and progression Endometrial Neoplasms - metabolism Endometrial Neoplasms - pathology Endometrium - metabolism Endometrium - pathology Female Health aspects Humans Immunohistochemistry Lymphatic Metastasis Neoplasm Invasiveness Ovarian cancer Patient outcomes Prognosis Proteins - metabolism Risk factors ROC Curve |
| title | Expression and clinical significance of annexin A2 and human epididymis protein 4 in endometrial carcinoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T06%3A43%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Expression%20and%20clinical%20significance%20of%20annexin%20A2%20and%20human%20epididymis%20protein%204%20in%20endometrial%20carcinoma&rft.jtitle=Journal%20of%20experimental%20&%20clinical%20cancer%20research&rft.au=Deng,%20Lu&rft.date=2015-09-11&rft.volume=34&rft.issue=1&rft.spage=96&rft.epage=96&rft.pages=96-96&rft.artnum=96&rft.issn=1756-9966&rft.eissn=1756-9966&rft_id=info:doi/10.1186/s13046-015-0208-8&rft_dat=%3Cgale_pubme%3EA541579659%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1780115284&rft_id=info:pmid/26362938&rft_galeid=A541579659&rfr_iscdi=true |